U.S. regulators have greenlit Eli Lilly’s tirzepatide, a drug formulated for the treatment of adult patients diagnosed with type 2 diabetes. Clinical studies indicate that tirzepatide, in conjunction with diet and physical activity, is more effective than other medications in normalizing blood glucose levels. Tirzepatide, designed for subcutaneous administration once per week, also supports obese patients in reducing their body weight by more than 20%. According to Eli Lilly, drug sales are predicted to reach a whopping $4.7 billion in 2026. Moreover, tirzepatide is the sole FDA-approved GIP and GLP-1 receptor agonist at present.